SCHEMBL2345247

SCHEMBL2345247

CCOc1cc(F)c(C(OC)C(=O)O)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.45
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
CAMKK1 Q8N5S9 1/20 0.37
CAMKK2 Q96RR4 1/20 0.37
FFAR1 O14842 6/20 0.37
PPARD Q03181 4/20 0.37
FFAR4 Q5NUL3 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
PTGS1 P23219 1/20 0.36
PPARA Q07869 2/20 0.36
PPARG P37231 1/20 0.36
CPS1 P31327 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2341607 0.86 PTGS2 (0.39) PTGS2CAMKK1CAMKK2FFAR1PPARD
SCHEMBL5037863 0.83 PTGS2 (0.42) PTGS2AKR1C3AKR1C2FFAR1FFAR4
SCHEMBL5038048 0.78 PTGS2 (0.39) PTGS2AKR1C3AKR1C2FFAR1PPARD
SCHEMBL5037903 0.78 PTGS2 (0.40) PTGS2AKR1C3AKR1C2ALDH1A1POLB
SCHEMBL5037527 0.74 CA12 (0.36) PTGS2FFAR1PTGS1PPARAPPARG
SCHEMBL5042575 0.74 PPARD (0.50) FFAR1PPARDPPARAPPARGMEN1
SCHEMBL5040747 0.73 CA12 (0.42) TDP1
SCHEMBL2345424 0.73 PTGS2 (0.43) PTGS2CAMKK1CAMKK2FFAR1PPARD
SCHEMBL2799007 0.73 PTGS2 (0.44) PTGS2CAMKK1CAMKK2FFAR1FFAR4
SCHEMBL2352769 0.73 ALDH1A1 (0.49) AKR1C3AKR1C2ALDH1A1POLBPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222645-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS HOFFMANN LA ROCHE (CH) 2013-03-20 EP disclosed
US-8008503-B2 Methyl-benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-30 US disclosed
US-20100331371-A1 METHYL-BENZIMIDAZOLE DERIVATIVES BENSON GREGORY MARTIN 2010-12-30 US disclosed
US-7825258-B2 Methyl-benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2222645-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2010-09-01 EP disclosed
WO-2009062874-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-05-22 WO disclosed
US-20090131482-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131482-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HDAC10, CYP3A4, ECI1 PTGS2 1040/4885AKR1C3 1423/4885AKR1C2 1700/4885
US-20100331371-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HDAC10, CYP3A4, ECI1 PTGS2 1040/4885AKR1C3 1423/4885AKR1C2 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.